Vireo GrowthFRA:K95 -5.39%44 Days Payable is 38.26 as of Mar. 2026, which is 177% above its 10-year median of 13.81. GuruFocus rates FRA:K95 with a GF Score™ of 44/100 and a GF Value™ of €7.54 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 923 Drug Manufacturers companies, Vireo Growth ranks worse than 86.78% on this metric.
The historical rank and industry rank for Vireo Growth's Days Payable or its related term are showing as below:
FRA:K95'
s Days Payable Range Over the Past 10 Years
Min: 11.11 Med: 13.81 Max: 34.07
Current: 34.07
During the past 13 years, Vireo Growth's highest Days Payable was 34.07. The lowest was 11.11. And the median was 13.81.
FRA:K95's Days Payable is ranked worse than 86.78% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs FRA:K95: 34.07
Vireo Growth's Days Payable
increased
from Mar. 2025 (33.32) to Mar. 2026 (38.26).
It may suggest that Vireo Growthdelayed paying its suppliers.
Vireo Growth Days Payable Related Terms
Vireo Growth Days Payable Historical Data
* Premium members only.
The historical data trend for Vireo Growth's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vireo Growth Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's Days Payable distribution charts can be found below:
* The bar in red indicates where Vireo Growth's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Vireo Growth's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vireo Growth (FRA:K95) has a Days Payable of 38.26 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vireo Growth and its competitors. This is 177% above median its historical median of 13.81. Over the past decade, Vireo Growth's Days Payable has ranged from 11.11 to 34.07. According to the industry distribution chart, Vireo Growth ranks #801 out of 923 companies in the Drug Manufacturers industry, placing it in the top 86.8%.
Is Vireo Growth's Days Payable too high?
Vireo Growth's current Days Payable of 38.26 is 177% above median its 10-year median of 13.81. Over the past 10 years, this metric has ranged from a low of 11.11 to a high of 34.07. The Drug Manufacturers industry median Days Payable is 90.98. Vireo Growth's value of 38.26 is 57.9% below this industry median. Based on the distribution chart, Vireo Growth ranks #801 out of 923 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vireo Growth has a GF Score™ of 44/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vireo Growth's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vireo Growth ranks #801 out of 923 companies for Days Payable. This places Vireo Growth in the lower half of its industry. The industry median Days Payable is 90.98. Vireo Growth's value of 38.26 is 57.9% below this benchmark. Historically, Vireo Growth's own Days Payable has ranged from 11.11 to 34.07 over the past decade. While the company's 10-year median is 13.81 vs. the industry median of 90.98, Vireo Growth has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vireo Growth's current Days Payable of 38.26 is 57.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vireo Growth and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vireo Growth's current Days Payable is 38.26, which is 177% above median its own 10-year median of 13.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vireo Growth stock overvalued right now?
Based on GuruFocus' analysis, Vireo Growth (FRA:K95) is currently considered Modestly Overvalued. The stock's GF Value™ is €7.54, compared to a current price of €8.42 — trading 11.7% above its estimated fair value. The current Days Payable is 38.26, which is 177% above median its 10-year median of 13.81 and 57.9% below the Drug Manufacturers industry median of 90.98. Vireo Growth's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Vireo Growth (FRA:K95), the current Days Payable is 38.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vireo Growth (FRA:K95) Overvalued in 2026?
Based on GuruFocus' analysis, Vireo Growth stock appears to be overvalued.
The current stock price of €8.42 is trading 11.7% above its estimated GF Value™ of €7.54.
GuruFocus considers Vireo Growth to be Modestly Overvalued.
Key valuation signals for FRA:K95:
Days Payable: 38.26 (177% above median its 10-year median of 13.81)
GF Value™: €7.54 vs. price of €8.42 (11.7% above fair value)
Industry Position: 57.9% below the Drug Manufacturers median (#801 of 923)
No single metric tells the full story. See the FRA:K95 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vireo Growth Incis a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. The company operates in one single segment.
44GF Score
Get the complete analysis for FRA:K95
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:K95 has been successfully added to your 
